Media ReleasesStar Combo Pharma

View All Star Combo Pharma News


Star Combo Announces FY2018 Results

Highlights

• Record full year revenue of $10.9million, up 10.8% on prior year.

• Underlying Profit is in line with expectations

• IPO costs(one-off) and non-cash share based payments expenses impact FY2018 profit

The Company has pleasure in announcing its operating results for the year ended 30 June 2018.

Revenue growth

Star Combo Pharma Ltd (“The Company or Star Combo”) derives its revenue through the manufacture and sale of vitamins and dietary supplements.


For further information please download PDF attached: 
Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.